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Purpose or Objective: The aim of this prospective study is 
the comparison of perfusion parameters changes (∆CTPp) 
before and after radio-chemotherapy (RCT) and their 
correlation with maximum standard uptake values variations 
(∆SUV max) among patients (pts) with head and neck tumor 
(HNT), in order to evaluate the prognostic value of perfusion 
CT parameters (CTPp) in predicting response to RCT. 
 
Material and Methods: We enrolled pts with intermediate 
and advanced stage of HNT (stage III-IV), candidated to RCT 
with curative intent. All pts underwent to a pretreatment 
diagnostic and staging workup including perfusion CT (CTP) 
and FDG-PET/CT total body. Pts also perform a CTP 3 weeks 
after the end of RCT (CTP3w) and both CTP and PET/CT 3 
months after the end of RCT (CTP3m and PET/CT 
repectively). We analised variations of following CTPp: Blood 
Flow (BF), Blood Volume (BV), Mean Transit Time (MTT) and 
Permeability-surface product (PS). All RCT treatments were 
performed using intensity modulated radiotherapy technique 
with simultaneous integrated boost. Prescribed doses were 66 
Gy at 2.2 Gy per fraction to high risk volume PTV and 60-54 
Gy at 2.0- 1.8 Gy per fraction respectively to intermediate 
(optional) and low risk PTVs, delivered in 30 daily fractions. 
Concurrent weekly Cisplatin 40 mg/ m2 or Cisplatin 100 
mg/m2 day 1, 22 an 43 was offered to all pts. 
 
Results: From July 2012 to July 2015 25 pts affected by stage 
III/IV HNT candidate to RCT were enrolled in our study. FDG-
PET/CT 3 months after the end of RCT showed a complete 
metabolic response in 16 pts (64%), a partial metabolic 
response in 7 pts (28%), a stable metabolic disease in 1 pts 
and progression metabolic disease in 1 pts (according PERCIS 
criteria). A significant reduction of all CTPp was observed 
from baseline CTP to CTP3w, except for MTT that did not 
show a significant variation (p=0,722). The analysis of 
differences between baseline CTP and CTP3m showed a 
significant reduction of all CTPp (p<0,001), including MTT 
(p=0,001). PET/CT response resulted statistically correlated 
to reduction of all CTPp both at 3 weeks and at 3 months 
after the end of RCT, except for MTT (p=0,998 and 0,692). At 
the multivariate analysis the PS was the only parameter that 
maintain a statistical significance at CTP3m (p=0,037) with a 
significant trend also at CTP3w(p=0,099). 
 
Conclusion: The induced damage on the intratumor 
microvascularization and low resistance flow of neoplastic 
vessels, explain the decrease of BV and BF whereas the 
reduction of neoangiogenesis phenomenon could explain the 
observed decrease of PS.Despite poor sample size, our 
preliminary results seem to be promising for a potential role 
of CTP to predict tumor response. PS seems the most 
valuable to predict the FDG-PET/CT tumor response. Due to 
the small sample size and short follow up, our results need to 
be confirmed in other series. Both funcional and 
morphological datas of the CTP can be usefull in order to 
reduce as much as possible the rate of false positive. 
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Purpose or Objective: The goal of this study is was to 
evaluate the results of treatment of T1N0M0 glottic cancer 
with irradiation, with emphasis on the influence of time from 
diagnosis to the beginning of radiation therapy. 
 
Material and Methods: We performed the retrospective 
analysis of the group of 539 patients with T1N0M0 glottic 
cancer, treated with radiation therapy in one institute 
between 1977 and 2004. In 481 cases (89%) the tumor was 
limited to single vocal cord and in the remaining 58 involved 
both of them. Anterior commisure involvement was observed 
in 173 (32%) of the patients. According to the radiotherapy 
technique and fractionation scheldule, we have divided 
patients into three separate groups: I - two oblique fields, TD 
60 Gy/24 - 277 patients (51%); II - two opposite fields, TD 60 
Gy/30 - 160 (31%); III - one lateral photon-electron beam, TD 
60 Gy/30 - 102 (19%). The average time from laryngeal biopsy 
to the beginning of radiotherapy was 56 days (range: 3 -145 
days).  
 
Results: The 5-year OS and 10-year OS were 84% and 69%, 5- 
and 10-year DFS were 90% and 88%, and the 5- and 10-year LC 
rates were 89% and 87%, respectively. One- dimensional 
analysis revealed following prognostic factors for LC and DFS: 
tobbaco smoking, radiotherapy technique, and the anterior 
commisure involvement. The 5- and 10-year LC rates in the 
group of patients smoking less than 20 cigarettes a day were 
90% and 87%, compared to 76% and 70%, respectively, in the 
group smoking more than 20 cigarettes a day (p=0,01). 
Considering the RT technique, the lowest 5- and 10-year LC 
rates were observed in the group treated with opposite 
beams (80% and 78%, respectively), and the highest when the 
oblique fields were used - 91% and 88%, respectively 
(p=0,002). The tumor involvement of the anterior commisure 
decreased 5-year LC by 15% (92 to 77%), and 10- year LC rate 
by 19% (89 to 70%, respectively, p=0,000). The waiting time 
for the beginning of RT longer than 30 days from the biopsy 
was statistically significant poor prognostic factor for DFS and 
LC. 5- and 10- year LC rates in the group of patients who 
started RT during the period of 30 days from the biopsy were 
92% and 90%, respectively, and in the group which started 
treatment after that time, these LC rates were 84% and 82%, 
respectively (p=0,01).  
 
Conclusion: Radiation therapy is efficient method of 
treatment the T1N0M0 glottic cancer. Prolonged time of 
waiting for the beginning of RT decreases the LC and DFS 
rates  
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Purpose or Objective: To evaluate the overall response rate 
and access the toxicity for patients with locally advanced 
squamous cell carcinoma of head and neck (HNSCC) receiving 
a novative docetaxel-based outpatient neoadjuvant 
chemotherapy regimen. 
 
Material and Methods: The inclusion criteria for this 
prospective study are (1)Age≧20 years old (2) Histologically 
proven squamous cell carcinoma of the oral cavity, 
oropharynx, hypopharynx, or larynx (3)Stage III or stage IVA 
or IVB without distant metastasis, (4) No prior chemotherapy 
given for HNSCC (5) Physician’s intention to treat with 
docetaxel- baed induction therapy (6) Patients’ informed 
consent will be obtained. Tumor response for induction 
chemotherapy will be evaluated in patient with measurable 
disease according to institutional guidance. The induction 
chemotherapy regimen is a novative outpatient regimen. This 
regimen consists of cisplatin 60mg/m2 on day 1, docetaxel 50 
mg/m2 on day 8, 5-Fu 2500 mg/m2 and leucovorin 250 
mg/m2 on day 15, and methotrexate 30 mg/m2 and 
epirubicin 30 mg/m2 on day 21, cycles will be repeated for a 
total 3 to 4 cycles followed by surgery or radiotherapy. 
Responses rate will be reported using Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria in patients with at 
least one measurable lesion. Toxicity will be recoreded using 
the NCI-CTC v.4.03. 
